Simple model for the study of Pseudomonas aeruginosa infections in leukopenic mice.

Infection and Immunity
S J CryzR Germanier

Abstract

A simple, reproducible model of fatal Pseudomonas aeruginosa sepsis in mice during immunosuppression was developed. Mice were rendered leukopenic (less than or equal to 800 leukocytes per mm3 of blood) for a period of 5 days by multiple injections of cyclophosphamide. Mice were challenged at the onset of leukopenia by instilling the bacteria onto a 0.5-mm incision made into the back. The mean lethal dose (LD50) for P. aeruginosa PA220 and M-2 was less than 20 bacteria. The mean time to death for these strains ranged from 46 to 59 h. Leukopenic mice were comparatively resistant when challenged with Klebsiella pneumoniae (LD50 = 1.5 x 10(6)) or Staphylococcus aureus (LD50 greater than 10(6)). Infection with P. aeruginosa was characterized by rapid bacterial multiplication in the skin at the site of infection, producing ecthyma gangrenosum. Bacteremia and colonization of the liver were pronounced 21 h postinfection. This model should prove to be a useful tool for studying the pathogenesis of P. aeruginosa infections under immunosuppressed conditions.

References

May 1, 1978·Journal of Medical Microbiology·B Wretlind, T Kronevi
Dec 1, 1977·Infection and Immunity·O R PavlovskisB H Iglewski
May 1, 1975·The American Journal of Medicine·J E PenningtonA S Levine
Nov 1, 1976·Infection and Immunity·L HarvathH J Amirault
Oct 1, 1973·Annals of Internal Medicine·L S YoungD Armstrong
Nov 1, 1974·The Journal of Infectious Diseases·M L Tapper, D Armstrong
Nov 1, 1974·The Journal of Infectious Diseases·S C SchimpffP H Wiernik
Jan 1, 1982·Infection and Immunity·I A HolderT C Montie

❮ Previous
Next ❯

Citations

Feb 16, 2019·Gastroenterology·Pramod K Garg, Vijay P Singh
Dec 1, 1987·Infection and Immunity·T R Anderson, T C Montie
Apr 1, 1990·Antimicrobial Agents and Chemotherapy·G S KobayashiG Medoff
Dec 1, 1987·Antimicrobial Agents and Chemotherapy·G S KobayashiG Medoff
Dec 1, 1996·Infection and Immunity·M GoughN M Kelly
Jun 17, 2021·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Alexander G BobrovVlado Antonic
Jul 13, 2021·Microbiology and Immunology·Shahinur AkterTomohiro Sawa

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.